Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Single-blinded, Placebo Controlled, Single Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of KJ103 in Healthy Subjects

NCT05274659 is registered in ClinicalTrials.gov with Shanghai Bao Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT05274659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05274659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Single-blinded, Placebo Controlled, Single Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of KJ103 in Healthy Subjects
Lead sponsor
Shanghai Bao Pharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 19, 2022
Completion date
August 18, 2023
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy